Apogee Therapeutics Inc.
Apogee Therapeutics Enters into Antibody Discovery and License Agreement with Paragon Therapeutics
Summary
On June 17, 2026, Apogee Therapeutics, Inc. entered into an antibody discovery agreement and a license agreement with Paragon Therapeutics, Inc. Under the antibody discovery agreement, Paragon will generate and characterize monospecific antibody candidates directed to interleukin 31 receptor (IL-31R), with potential additional fees for manufacturing and control activities. The license agreement grants Apogee an exclusive, worldwide, royalty-bearing license to use, make, sell, import, export, and otherwise exploit antibodies directed at the IL-31R target, with Paragon retaining non-exclusive rights to develop, manufacture, commercialize, and exploit multispecific antibodies. Apogee is obligated to pay Paragon up to $23.25 million upon achieving specific development, clinical, and regulatory milestones and royalties based on net sales of products. The agreements can be terminated under various conditions, including material breach, insolvency, or bankruptcy.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement